A Phase 2 interventional study of REGN3918 in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Regeneron Pharmaceuticals. Completed at 12 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-26.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2019, is one of 3 in phase 2, and was the 1st registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Brazil, Canada, Italy and 4 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Canada, Korea, Republic of, United Kingdom
Ages 18+
Regeneron Pharmaceuticals · Sites in Brazil, Canada, Colombia and 18 more countries
Ages 18+
By country, each count listing its studies:
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5
First in 2019; this study’s year is marked. 2 started in 2019.
This study's enrollment of 24 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 24 across the 9 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to demonstrate a reduction in intravascular hemolysis by REGN3918 over 26 weeks of treatment in patients with active PNH who are treatment-naive to complement inhibitor therapy or have not recently received complement inhibitor therapy.
The secondary objectives of the study are:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort A (Dose Confirmation) If a decision is made to expand Cohort A, patients will be assigned to Cohort A. Cohort B (Dose Expansion) If a decision is made to progress to Cohort B, patients will be assigned to Cohort B.
Drug: REGN3918
Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
Percentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis
Participants were considered to have had adequate control of intravascular hemolysis if all of their lactose dehydrogenase (LDH) readings from Week 4 through Week 26 inclusive had values less than or equal to ≤ 1.5 × upper limit of normal (ULN). Participants must have greater than or equal to (≥) 50 percent (%) of scheduled LDH measures in those weeks, must not have had more than (\>) 2 consecutive visits without LDH measures, must not have experienced breakthrough hemolysis, and must not have discontinued study treatment early. Participants were considered not to have had adequate control of intravascular hemolysis if they failed any of these criteria.
Time frame: Week 4 through Week 26
Percentage of Participants Who Achieved Transfusion Avoidance
Transfusion avoidance was defined as not having received red blood cell (RBC) transfusion during the first 26 weeks. A transfusion was counted only if it was per-protocol, that is, it followed the predefined transfusion algorithm: RBC transfusion due to a post-baseline hemoglobin level \< 9 grams per deciliter (g/dL) (with anemia symptoms) or a post-baseline hemoglobin level \< 7 g/dL (without anemia symptoms).
Time frame: Up to 26 Weeks
Percentage of Participants Who Had Breakthrough Hemolysis (BTH)
Breakthrough hemolysis was defined as the measurement of LDH ≥ 2 ULN concomitant with associated signs or symptoms at any time subsequent to an initial achievement of disease control (i.e., LDH ≤ 1.5 ULN).
Time frame: Baseline up to 26 Weeks
Percentage of Participants Who Achieved Normalization of Intravascular Hemolysis
A participant was considered to have achieved normalization of intravascular hemolysis if their LDH readings between Week 4 through Week 26 inclusive had values ≤ 1.0 ULN. A participant must have ≥ 50% of scheduled LDH measures in those weeks, must not have had \> 2 consecutive visits without LDH measures, must not have experienced breakthrough hemolysis, and must not have discontinued study treatment early. A participant was considered not to have achieved normalization of intravascular hemolysis if they failed any of these criteria.
Time frame: Week 4 through Week 26
Time to First Lactate Dehydrogenase (LDH) ≤1.5 x ULN
A time-to-first-event analysis was used to estimate the proportion of participants achieving transfusion avoidance at Week 26.
Time frame: Up to Week 26
Percentage of Days With LDH ≤ 1.5 ULN From Week 4 Through Week 26
Percentage of days was calculated as number of days with LDH ≤ 1.5 x ULN divided by the participant's total treatment duration (total number of days on treatment from Week 4 through Week 26). LDH ≤ 1.5 x ULN was used as an indicator of adequate control of intravascular hemolysis.
Time frame: Week 4 through Week 26
Change From Baseline in LDH Levels at Week 26
Change from baseline in LDH levels at Week 26 was reported.
Time frame: Baseline, Week 26
Percent Change From Baseline in LDH Levels at Week 26
Percent change from baseline in LDH levels at Week 26 was reported.
Time frame: Baseline, Week 26
Rate of Transfusion With Red Blood Cells (RBCs)
The rate of transfusion with RBCs for a participant was the total number of transfusions divided by total person-years of time on treatment.
Time frame: Baseline up to Week 26
Number of Units of Transfusion With RBCs
Transfusions with RBCs proceeded according to the following predefined criteria that triggered a transfusion; however, the actual number of units to be transfused is at the discretion of the investigator: • Transfuse with RBC(s) if the post-baseline hemoglobin level is \<9 g/dL with symptoms resulting from anemia or • Transfuse with RBC(s) if the post-baseline hemoglobin level is \<7 g/dL.
Time frame: Baseline up to Week 26
Change From Baseline in RBC Hemoglobin Levels at Week 26
Hemoglobin levels in participants with PNH was measured. Change from baseline in RBC hemoglobin at Week 26 was reported.
Time frame: Baseline, Week 26
Change From Baseline in Free Hemoglobin Levels at Week 26
Change from baseline in free hemoglobin levels at Week 26 was assessed.
Time frame: Baseline, Week 26
Change From Baseline in Total Complement Hemolytic Activity Assay (CH50) at Week 26
Change from baseline in total CH50 at Week 26 was reported. Here "International units per milliliter" was abbreviated as "IU/mL".
Time frame: Baseline, Week 26
Percent Change From Baseline in CH50 up to Week 26
Percent change from baseline in CH50 up to Week 26 was reported.
Time frame: Baseline up to Week 26
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 26
The FACIT-F was a 13-item, self-reported PRO measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire was part of the FACIT measurement system, a compilation of questions measuring health-related QoL in participants with cancer and other chronic illnesses. The FACIT-fatigue assessed the level of fatigue using a 4-point Likert scale ranging from 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much) The sum of all responses resulted in the FACIT-F score for a total possible score of 0 to 52, with higher scores indicated greater fatigue.
Time frame: Baseline, Week 26
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-core 30 (EORTC QLQ-C30) at Week 26
The EORTC QLQ-C30 was a 30-item questionnaire used to assess symptoms and side effects of treatment and the impact on everyday life. It consists of 15 domains: 5 multi-item functioning scales (physical, role, social, emotional and cognitive), answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much). Each score ranges from 0-100 with a higher score indicates higher level of functioning and a better QoL. A global health status/QoL scale that was answered on a 7-point scale (1=Very Poor to 7=Excellent). Each score ranges from 0-100 with a higher score indicates a better QoL. 9 symptom scales (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact), answered on a 4-point scale (1=Not at all, 2=A Little, 3=Quite a Bit, 4=Very Much). Each score ranges from 0 to 100 with a higher score indicates a higher level of symptoms, and a negative change from baseline indicates an improvement in symptoms.
Time frame: Baseline, Week 26
Change From Baseline in European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Index Score
EQ-5D-3L was a self-administered standardized instrument for use as measure of health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension rated on 3 levels scale: 1 (no problems), 2 (some problems), 3 (extreme problems). The summed score ranges from 5-15 with "5" corresponding to no problems and "15" to severe problems in 5 dimensions. EQ-5D index calculated by applying preference-based weights (tariffs) to scores of five health state dimensions. Index values range from -1 to 1, with 0 representing a health state equivalent to death and 1 representing perfect health. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best).
Time frame: Baseline, Week 26
Change From Baseline in EQ-5D-3L Visual Analogue Scale (VAS) at Week 26
The EQ-5D-3L was a standardized instrument for use as a measure of health outcome and was administered to all participants to assess the effect of the treatment on the participants' quality of life. The EQ-5D-3L includes a visual analog scale (VAS) which is a vertical scale with numbers ranging from 0 to 100. Participants were asked to draw a line to the place on the scale that best represented how good or bad his health was on that day. The worst state a participant can imagine was marked zero, and the best state the participant can imagine was marked 100. Mean change in VAS score from baseline was reported.
Time frame: Baseline, Week 26
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs was defined as AEs that developed or worsened during the on-treatment period. SAE was defined as any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline up to Week 26
Number of Participants With TEAEs Based on Severity
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Severity of AEs was graded according to the following scale, Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.
Time frame: Baseline up to Week 26
Number of Participants With Clinically Meaningful Changes in Clinical Laboratory Parameters
Clinical laboratory parameters included biochemistry, hematology and urinalysis. Number of participants with potential clinically significant changes in laboratory parameters which were deemed clinically meaningful by the investigator were reported.
Time frame: Baseline up to Week 26
Number of Participants With Clinically Meaningful Changes in Vital Signs
Vital sign assessments included pulse rate, blood pressure (systolic and diastolic blood pressure) and body temperature. Number of participants with potential clinically meaningful changes in vital signs which were deemed clinically significant by the investigator were reported.
Time frame: Baseline up to Week 26
Number of Participants With Clinically Meaningful Changes in 12-lead Electrocardiograms (ECGs)
12-lead ECGs were evaluated. Any change in ECG assessments which are deemed clinically meaningful by the investigator were reported.
Time frame: Baseline up to Week 26
Serum Concentrations of Total REGN3918
Serum Concentrations of total REGN3918 was reported.
Time frame: Pre-dose (Day 0), End of infusion at Days 0, 2, 7, 28, 56, 84, 112, 140, and 182
Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADA) Response to REGN3918
Number of Participants with treatment-emergent ADA response to REGN3918 was reported.
Time frame: Baseline up to Week 26
| Milestone | REGN3918 |
|---|---|
| Started | 24 |
| Completed | 24 |
| Not completed | 0 |
Participants were considered to have had adequate control of intravascular hemolysis if all of their lactose dehydrogenase (LDH) readings from Week 4 through Week 26 inclusive had values less than or equal to ≤ 1.5 × upper limit of normal (ULN). Participants must have greater than or equal to (≥) 50 percent (%) of scheduled LDH measures in those weeks, must not have had more than (\>) 2 consecutive visits without LDH measures, must not have experienced breakthrough hemolysis, and must not have discontinued study treatment early. Participants were considered not to have had adequate control of intravascular hemolysis if they failed any of these criteria.
| Percentage of Participants | REGN3918 |
|---|---|
| Percentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis | 75.0 (57.7 to 92.3) |
Transfusion avoidance was defined as not having received red blood cell (RBC) transfusion during the first 26 weeks. A transfusion was counted only if it was per-protocol, that is, it followed the predefined transfusion algorithm: RBC transfusion due to a post-baseline hemoglobin level \< 9 grams per deciliter (g/dL) (with anemia symptoms) or a post-baseline hemoglobin level \< 7 g/dL (without anemia symptoms).
| Percentage of Participants | REGN3918 |
|---|---|
| Percentage of Participants Who Achieved Transfusion Avoidance | 87.5 (74.3 to 100.0) |
Breakthrough hemolysis was defined as the measurement of LDH ≥ 2 ULN concomitant with associated signs or symptoms at any time subsequent to an initial achievement of disease control (i.e., LDH ≤ 1.5 ULN).
| Percentage of Participants | REGN3918 |
|---|---|
| Percentage of Participants Who Had Breakthrough Hemolysis (BTH) | 0 (0 to 0) |
A participant was considered to have achieved normalization of intravascular hemolysis if their LDH readings between Week 4 through Week 26 inclusive had values ≤ 1.0 ULN. A participant must have ≥ 50% of scheduled LDH measures in those weeks, must not have had \> 2 consecutive visits without LDH measures, must not have experienced breakthrough hemolysis, and must not have discontinued study treatment early. A participant was considered not to have achieved normalization of intravascular hemolysis if they failed any of these criteria.
| Percentage of Participants | REGN3918 |
|---|---|
| Percentage of Participants Who Achieved Normalization of Intravascular Hemolysis | 16.7 (1.8 to 31.6) |
A time-to-first-event analysis was used to estimate the proportion of participants achieving transfusion avoidance at Week 26.
| Days | REGN3918 |
|---|---|
| Time to First Lactate Dehydrogenase (LDH) ≤1.5 x ULN | 13.625 ± 3.6927 |
Percentage of days was calculated as number of days with LDH ≤ 1.5 x ULN divided by the participant's total treatment duration (total number of days on treatment from Week 4 through Week 26). LDH ≤ 1.5 x ULN was used as an indicator of adequate control of intravascular hemolysis.
| Percentage of Days | REGN3918 |
|---|---|
| Percentage of Days With LDH ≤ 1.5 ULN From Week 4 Through Week 26 | 93.4 ± 18.76 |
Change from baseline in LDH levels at Week 26 was reported.
| Units per liter (U/L) | REGN3918 |
|---|---|
| Change From Baseline in LDH Levels at Week 26 | -5.070 ± 0.1467 |
Percent change from baseline in LDH levels at Week 26 was reported.
| Percent Change | REGN3918 |
|---|---|
| Percent Change From Baseline in LDH Levels at Week 26 | -81.72 ± 1.847 |
The rate of transfusion with RBCs for a participant was the total number of transfusions divided by total person-years of time on treatment.
| Infusions Per Participant Year | REGN3918 |
|---|---|
| Rate of Transfusion With Red Blood Cells (RBCs) | 1.039 (0.187 to 5.772) |
Transfusions with RBCs proceeded according to the following predefined criteria that triggered a transfusion; however, the actual number of units to be transfused is at the discretion of the investigator: • Transfuse with RBC(s) if the post-baseline hemoglobin level is \<9 g/dL with symptoms resulting from anemia or • Transfuse with RBC(s) if the post-baseline hemoglobin level is \<7 g/dL.
| Number of units of transfusions of RBC | REGN3918 |
|---|---|
| Number of Units of Transfusion With RBCs | 3.625 ± 4.274 |
Hemoglobin levels in participants with PNH was measured. Change from baseline in RBC hemoglobin at Week 26 was reported.
| grams per liter (g/L) | REGN3918 |
|---|---|
| Change From Baseline in RBC Hemoglobin Levels at Week 26 | 15.0 ± 3.24 |
Change from baseline in free hemoglobin levels at Week 26 was assessed.
| milligrams per deciliter (mg/dL) | REGN3918 |
|---|---|
| Change From Baseline in Free Hemoglobin Levels at Week 26 | -9.19 ± 16.264 |
Change from baseline in total CH50 at Week 26 was reported. Here "International units per milliliter" was abbreviated as "IU/mL".
| IU/mL | REGN3918 |
|---|---|
| Change From Baseline in Total Complement Hemolytic Activity Assay (CH50) at Week 26 | -236.6 ± 0.65 |
Percent change from baseline in CH50 up to Week 26 was reported.
| Percent Change | REGN3918 |
|---|---|
| Percent Change From Baseline in CH50 up to Week 26 | -99.99 ± 0.243 |
The FACIT-F was a 13-item, self-reported PRO measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire was part of the FACIT measurement system, a compilation of questions measuring health-related QoL in participants with cancer and other chronic illnesses. The FACIT-fatigue assessed the level of fatigue using a 4-point Likert scale ranging from 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much) The sum of all responses resulted in the FACIT-F score for a total possible score of 0 to 52, with higher scores indicated greater fatigue.
| Score on a Scale | REGN3918 |
|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 26 | 9.9 ± 1.52 |
The EORTC QLQ-C30 was a 30-item questionnaire used to assess symptoms and side effects of treatment and the impact on everyday life. It consists of 15 domains: 5 multi-item functioning scales (physical, role, social, emotional and cognitive), answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much). Each score ranges from 0-100 with a higher score indicates higher level of functioning and a better QoL. A global health status/QoL scale that was answered on a 7-point scale (1=Very Poor to 7=Excellent). Each score ranges from 0-100 with a higher score indicates a better QoL. 9 symptom scales (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact), answered on a 4-point scale (1=Not at all, 2=A Little, 3=Quite a Bit, 4=Very Much). Each score ranges from 0 to 100 with a higher score indicates a higher level of symptoms, and a negative change from baseline indicates an improvement in symptoms.
| Score on a Scale | REGN3918 |
|---|---|
| Global Health status/quality: Change at Week 26 | 12.509 ± 3.2286 |
| Physical Functioning: Change at Week 26 | 17.511 ± 2.6767 |
| Emotional Functioning: Change at Week 26 | 14.457 ± 3.8645 |
| Social Functioning: Change at Week 26 | 15.846 ± 3.8036 |
| Fatigue: Change at Week 26 | -18.904 ± 2.9899 |
| Pain: Change at Week 26 | -13.537 ± 3.0315 |
| Dyspnea: Change at Week 26 | -15.874 ± 4.7953 |
| Cognitive Functioning: Change at Week 26 | 9.840 ± 2.9710 |
EQ-5D-3L was a self-administered standardized instrument for use as measure of health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension rated on 3 levels scale: 1 (no problems), 2 (some problems), 3 (extreme problems). The summed score ranges from 5-15 with "5" corresponding to no problems and "15" to severe problems in 5 dimensions. EQ-5D index calculated by applying preference-based weights (tariffs) to scores of five health state dimensions. Index values range from -1 to 1, with 0 representing a health state equivalent to death and 1 representing perfect health. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best).
| Score on a Scale | REGN3918 |
|---|---|
| Change From Baseline in European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Index Score | 0.136 ± 0.0238 |
The EQ-5D-3L was a standardized instrument for use as a measure of health outcome and was administered to all participants to assess the effect of the treatment on the participants' quality of life. The EQ-5D-3L includes a visual analog scale (VAS) which is a vertical scale with numbers ranging from 0 to 100. Participants were asked to draw a line to the place on the scale that best represented how good or bad his health was on that day. The worst state a participant can imagine was marked zero, and the best state the participant can imagine was marked 100. Mean change in VAS score from baseline was reported.
| Score on a Scale | REGN3918 |
|---|---|
| Change From Baseline in EQ-5D-3L Visual Analogue Scale (VAS) at Week 26 | 8.4 ± 2.18 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs was defined as AEs that developed or worsened during the on-treatment period. SAE was defined as any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | REGN3918 |
|---|---|
| Participants with TEAEs | 21 |
| Participants with Serious TEAEs | 0 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Severity of AEs was graded according to the following scale, Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.
| Participants | REGN3918 |
|---|---|
| Participants with Mild TEAEs | 13 |
| Participants with Moderate TEAEs | 6 |
| Participants with Severe TEAEs | 2 |
Clinical laboratory parameters included biochemistry, hematology and urinalysis. Number of participants with potential clinically significant changes in laboratory parameters which were deemed clinically meaningful by the investigator were reported.
| Participants | REGN3918 |
|---|---|
| Hematology | 13 |
| Chemistry | 17 |
| Urinalysis | 0 |
Vital sign assessments included pulse rate, blood pressure (systolic and diastolic blood pressure) and body temperature. Number of participants with potential clinically meaningful changes in vital signs which were deemed clinically significant by the investigator were reported.
| Participants | REGN3918 |
|---|---|
| Number of Participants With Clinically Meaningful Changes in Vital Signs | 12 |
12-lead ECGs were evaluated. Any change in ECG assessments which are deemed clinically meaningful by the investigator were reported.
| Participants | REGN3918 |
|---|---|
| Number of Participants With Clinically Meaningful Changes in 12-lead Electrocardiograms (ECGs) | 0 |
Serum Concentrations of total REGN3918 was reported.
| Milligram/liter (mg/L) | REGN3918 |
|---|---|
| At Day 0 (Pre-dose) | 0 ± 0 |
| At Day 0 (End of Infusion) | 605 ± 214 |
| At Day 2 (End of Infusion) | 429 ± 159 |
| At Day 7 (End of Infusion) | 292 ± 80.5 |
| At Day 28 (End of Infusion) | 324 ± 97.5 |
| At Day 56 (End of Infusion) | 368 ± 148 |
| At Day 84 (End of Infusion) | 363 ± 152 |
| At Day 112 (End of Infusion) | 379 ± 186 |
| At Day 140 (End of Infusion) | 430 ± 225 |
| At Day 182 (End of Infusion) | 435 ± 221 |
Number of Participants with treatment-emergent ADA response to REGN3918 was reported.
| Participants | REGN3918 |
|---|---|
| Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADA) Response to REGN3918 | 0 |
Collected over From first dose to Week 26. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| REGN3918 | 0/24 (0%) | 0/24 (0%) | 13/24 (54.2%) |
| Event | REGN3918 |
|---|---|
| HeadacheNervous system disorders | 9/24 |
| Abdominal painGastrointestinal disorders | 3/24 |
| NasopharyngitisInfections and infestations | 3/24 |
| Injection site reactionGeneral disorders | 3/24 |
| NauseaGastrointestinal disorders | 2/24 |
| Upper respiratory tract infectionInfections and infestations | 2/24 |
The safety analysis set (SAF) included all enrolled participants who received any study drug.
| Age, Continuous(Years) | REGN3918 |
|---|---|
| Mean | 45.4 ± 17.28 |
| Sex: Female, Male(Participants) | REGN3918 |
|---|---|
| Female | 11 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | REGN3918 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | REGN3918 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 21 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 2 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from May 2019 to primary completion in Jun 2021, 24 months.
Results were first posted in Jun 2023, 2 years after primary completion.
Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 24 months is above that.
Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pozelimab